BPC-157 10mg
$59.99
BPC-157 10mg
Body Protection Compound-157
CAS: 137525-51-0
BPC-157 (Body Protection Compound-157) 10mg — the gut guardrail of the Clav stack. 36+ preclinical studies, no minimum toxic dose found.
For research purposes only. Not intended for human use.
Gastroprotection via NO System, VEGFR2, and Cytoprotective Pathways
BPC-157 is a 15-amino acid pentadecapeptide (GEPPPGKPADDAGLV) derived from gastric juice. It modulates the eNOS/NO system, upregulating nitric oxide production to increase mucosal blood flow. It activates VEGFR2 to drive angiogenesis in healing tissue and upregulates EGF receptor expression supporting mucosal repair. In the Clav stack, BPC-157 is run from day 1 of any GLP protocol to counteract the gastroparesis and altered gut motility caused by GLP-1 receptor activation.
GI Protection During GLP Protocols
Retatrutide Phase 2 reported nausea in 43% of participants and diarrhea in 34%. BPC-157's gastroprotective mechanism — NO system upregulation, tight junction repair, mucosal VEGF — directly addresses the GI stress caused by GLP dose escalation. Run from day 1, not as a reactive measure.
36+ Preclinical Studies
BPC-157 has one of the most extensive preclinical research profiles of any peptide in the catalog — 36+ published studies from Sikiric et al. at the University of Zagreb covering GI healing, tendon repair, neuroprotection, and anti-inflammatory effects.
No Minimum Toxic Dose
Rodent safety studies on BPC-157 have not identified a minimum toxic dose — a rare finding in peptide research. This broad safety profile supports its inclusion as an always-on stack component.
Specifications
Research FAQ
When do I start BPC-157 in the Clav protocol?
Day 1 — concurrent with Retatrutide initiation. BPC-157 works prophylactically, not reactively. Starting it before GI symptoms appear is the Clav stack approach.
Can I combine BPC-157 with TB-500?
Yes — frequently co-administered. BPC-157 covers gastric/mucosal protection; TB-500 addresses connective tissue and systemic tissue repair. Different mechanisms, complementary effects.
